王栋栋

个人简历

王栋栋，男，临床药学博士，讲师，执业药师，硕士生导师，江苏省“双创博士”，2021年毕业于复旦大学（与美国密歇根大学联合培养，国家公派留学）。研究方向为模型引导的临床精准用药、儿科临床药理学与毒理学。主持国家自然基金、市、校级科研课题4项；以（共）第一/通讯作者在Front Pharmacol、Eur J Pharm Sci、Front Nutr、Expert Rev Clin Pharmacol、J Diabetes Res、J Clin Pharm Ther等发表SCI论文30篇，教学论文2篇；担任Front Pharmacol（中科院2区）客座副主编，Model-informed drug development and precision dosing in clinical pharmacology practice研究专题客座主编；同时为8本SCI期刊审稿人。担任中华医学会第二十三次全国儿科学术大会临床药理学分会主持人；受邀在中国儿科药物基因组学联盟成立大会上做专题报告；受邀参加第十七届欧洲发育围产期和儿科药理学大会（瑞士，巴塞尔）；在亚洲临床药学会议（新加坡）、中华医学会临床药学分会、中华医学会全国儿科学术大会、中华医学会肾脏病学分会、全国儿科药学学术年会、全国治疗药物监测学术年会上大会发言、交流及获奖10余次。

承担科研课题

1. 国家自然科学基金青年科学基金项目，82104296，CXCR2通过PI3K/AKT/mTOR通路调控他克莫司诱导儿童肾毒性的机制研究，2022.01-2024.12，30万元，主持

2. 徐州市推动科技创新专项资金重点研发计划（社会发展），KC21257，基于临床药学关键前沿技术PBPK/PPK/PD/PG的儿童患者免疫抑制剂精准治疗，2021.09-2023.08，6万元，主持

3. 徐州医科大学优秀人才科研启动基金，D2021012，模型引导的免疫抑制剂精准治疗，2021.05-2024.04，20万元，主持

4. 徐州医科大学“融合创新”项目，XYRHCX2021011，基于模型引导的药物研发新模式：推荐防治GVHD的新药在临床试验中给药方案，2021.07-2024.07，3万元，主持

近五年代表性论文、专著

1.    Wang DD, Zhang C, Hu K, He SM, Zhu P, Chen X. Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients. Front Pharmacol. 2023 Jan 4;13:972878. IF:5.988

2.    Wang DD, Zhang C, Zhu P, He SM, Chen X. Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients. Front Pharmacol. 2022 Nov 28;13:910858. IF:5.988

3.    Wang DD, Li YF, Zhang C, He SM, Chen X. Predicting the effect of sirolimus on disease activity in patients with systemic lupus erythematosus using machine learning. J Clin Pharm Ther. 2022 Nov;47(11):1845-1850. IF:2.145

4.    Wang DD, Li YF, Mao YZ, He SM, Zhu P, Wei QL. A machine-learning approach for predicting the effect of carnitine supplementation on body weight in patients with polycystic ovary syndrome. Front Nutr. 2022 Aug 10;9:851275. IF:6.590

5.    Wang DD, Zhang C, Yang Y, He SM, Zhu P, Chen X. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care. J Diabetes Res. 2022 Jul 20;2022:5854200. IF:4.061

6.    Wang DD, Mei YQ, Yang L, Ding KW, Xue JJ, Wang X, He SM, Wei QL. Optimization of initial dose regimen of tacrolimus in paediatric lung transplant recipients based on Monte Carlo simulation. J Clin Pharm Ther. 2022 Oct;47(10):1659-1666. IF:2.145

7.    Wang DD, He SM, Yang Y, Mao YZ, Yin D, Zheng ZQ, Chen X. Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients. Eur J Pharm Sci. 2022 Jul 1;174:106183. IF:5.112

8.    Wang DD, Mao YZ, Yang Y, Wang TY, Zhu P, He SM, Chen X. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. J Diabetes Res. 2022 Mar 18;2022:4491900. IF:4.061

9.    Wang DD, Wang TY, Yang Y, He SM, Wang YM. The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients. Front Nutr. 2021 Nov 8;8:748075. IF:6.590

10. Wang DD, He SM, Han Y, Wang TY, Wang YM. Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients. J Clin Pharm Ther. 2022 Feb;47(2):237-242. IF:2.145

11. Wang DD, Mao YZ, He SM, Chen X. Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents. Front Pharmacol. 2021 Apr 26;12:611480. IF:5.988

12. Wang DD, Mao YZ, He SM, Yang Y, Chen X. Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients. Expert Rev Clin Pharmacol. 2021 Jul;14(7):919-926. IF:4.108

13. Wang DD, Chen X, Xu H, Li ZP. Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex. Front Pharmacol. 2020 Jun 11;11:890. IF:5.988

14. Wang D, Chen X, Fu M, Xu H, Li Z. Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. Int J Mol Med. 2019 Dec;44(6):2181-2188. IF:5.314